



Rosemary Kellogg
rkellogg@sbiplaw.com

February 14, 2006

John Harre
Archemix Corporation
300 Third Street
Cambridge MA 02139

Re: U.S. Patent Application Serial No. 10/606,159
Platelet Derived Growth Factor (PDGF)
Nucleic Acid Ligand Complexes
Our Ref.: NEX 66/D2

Dear John:

Enclosed is a Response to Office Action filed in the referenced case. We will continue to keep you apprised of developments in this matter as they occur.

Should you have any questions, please do not hesitate to contact me.

Very truly yours,

Rosemary Kellogg

RK;tec
Enclosures
S:\ClientFolders\Gilead (formerly NeXstar)\Nex66\D2\harre06.doc



IFW

Attorney Docket No. NEX66/D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JANJIC *et al.*

SERIAL NO.: 10/606,159

FILED: JUNE 24, 2003

TITLE: PLATELET DERIVED GROWTH
FACTOR (PDGF) NUCLEIC ACID
LIGAND COMPLEXES

EXAMINER: VIVLEMORE, T. A.

ART UNIT: 1635

CONF. NO. 3567

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

Dear Sir:

An Office Action was mailed in the above-captioned application on February 2, 2006. In such Office Action pending claims 1-8 were subject to a restriction and/or election requirement. This document is submitted in response to said Office Action.

Claims as filed are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Feb. 14, 2006.

Signature:

Name: Tracy E. Crispino